Formulation and evaluation of transdermal patches containing dexketoprofen trometamol

Trivedi, D.M.; Goyal, Anju

doi:10.18231/j.ijpca.2020.014

Cited by 12 publications

(15 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results indicated that the formulated patches would not break or crack with skin folding. The greater folding endurance was obtained in those formulated patches containing higher amount of hydrophilic polymers (HPMC) as compared to the formulations containing higher amount of hydrophobic polymer (Eudragit S-100) [ 33 ]. Folding endurance of formulated patches showed 61 ± 3.14 to 74 ± 2.32 ( Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

Formulation of Polymers-Based Methotrexate Patches and Investigation of the Effect of Various Penetration Enhancers: In Vitro, Ex Vivo and In Vivo Characterization

et al. 2022

View full text Add to dashboard Cite

The present study aimed to prepare methotrexate-loaded transdermal patches with different blends of hydrophobic and hydrophilic polymers (Eudragit S-100 and hydroxypropyl methylcellulose) at different concentrations. The polymers employed in transdermal patches formulations served as controlled agent. Transdermal patches were prepared using the solvent casting technique. The suitable physicochemical properties were obtained from the formulation F5 (HPMC and Eudragit S-100 (5:1). Various penetration enhancers were employed in different concentrations to investigate their potential for enhancing the drug permeation profile from optimized formulations. A preformulation study was conducted to investigate drug–excipient compatibilities (ATR-FTIR) and the study showed greater compatibility between drug, polymers and excipients. The prepared patches containing different penetration enhancers at different concentrations were subjected for evaluating different physicochemical parameters and in vitro drug release studies. The obtained data were added to various kinetic models, then formulated patch formulations were investigated for ex vivo permeation studies, in vivo studies and skin drug retention studies. The prepared patches showed elastic, smooth and clear nature with good thickness, drug content, % moisture uptake and weight uniformity. The prepared transdermal patches showed % drug content ranging from 91.43 ± 2.90 to 98.37 ± 0.56, % swelling index from 36.98 ± 0.19 to 75.32 ± 1.21, folding endurance from 61 ± 3.14 to 78 ± 1.54 and tensile strength from 8.54 ± 0.18 to 12.87 ± 0.50. The formulation F5, containing a greater amount of hydrophilic polymers (HPMC), showed increased drug release and permeation and drug retention when compared to other formulated transdermal patch formulations (F1-F9). No significant change was observed during a stability study for a period of 60 days. The rabbit skin samples were subjected to ATR-FTIR studies, which revealed that polymers and penetration enhancers have affected skin proteins (ceramides and keratins). The pharmacokinetic profiling of optimized formulation (F5) as well as formulations with optimized concentrations of penetration enhancers revealed Cmax ranged 167.80 ng/mL to 178.07 ± 2.75 ng/mL, Tmax was 8 h to 10 h, and t1/2 was 15.9 ± 2.11 to 21.49 ± 1.16. From the in vivo studies, it was revealed that the formulation F5-OA-10% exhibited greater skin drug retention as compared to other formulations. These results depicted that prepared methotrexate transdermal patches containing different blends of hydrophobic and hydrophilic polymers along with different penetration enhancers could be safely used for the management of psoriasis. The formulated transdermal patches exhibited sustained release of drug with good permeations and retention profile. Hence, these formulated transdermal patches can effectively be used for the management of psoriasis.

show abstract

Section: Resultsmentioning

confidence: 99%

Formulation of Polymers-Based Methotrexate Patches and Investigation of the Effect of Various Penetration Enhancers: In Vitro, Ex Vivo and In Vivo Characterization

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The transdermal patch was cut into 2 cm squares to measure weight variation, and three pieces were weighed to calculate the average weight [16][17][18][19][20] .…”

Section: Weight Variationmentioning

confidence: 99%

“…A vernier caliper was used to measure the thickness of the three patches. Thickness was measured at three different points on the patch and the average value was recorded [16][17][18][19][20] .…”

Section: Thicknessmentioning

confidence: 99%

Formulation and evaluation of Ketorolac tromethamine for transdermal drug delivery system

Giddam¹,

AnieVijetha²

2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

Nonsteroidal anti-inflammatory drugs (NSAIDs) such as Ketorolac Tromethamine are widely recommended to treat pain caused by osteoarthritis, ankylosing spondylitis, acute sciatica, rheumatoid arthritis and low back pain. Modern drug delivery technology, such as transdermal patches, is mostly used in the treatment of numerous diseases. As first-pass metabolism is avoided. Transdermal drug delivery systems (TDDS) can efficiently enhance bioavailability and help with the planned and controlled release of drug molecules into the systemic circulation. The purpose of this work was to produce matrix-type Ketorolac tromethamine transdermal patches by solvent evaporation using different polymer ratios, such as HPMC 15 cps, HPMC E5, and Eudragit S 100. Along with solvents like methanol and chloroform, plasticizers like glycerine, propylene glycol, and PEG 200 are used in this formulation. According to the FTIR study, Ketorolac Tromethamine had no significant interactions with other excipients. The following evaluations are carried out such as thickness, weight variation, folding durability, moisture content, drug content, surface pH, and In vitro diffusion are all evaluated for the prepared patches.

show abstract

“…Here the optimized ilm and is taken and the different composition of gels are added to it and this composition was prepared and further evaluation (Table 5) [6].…”

Section: Preparation Of Transdermal Patch With Different Gel Compositionmentioning

confidence: 99%

Test title

Prakash¹

2021

Fut J. Pharm & H. Sci

View full text Add to dashboard Cite

show abstract

Formulation and evaluation of transdermal patches containing dexketoprofen trometamol

Cited by 12 publications

References 14 publications

Formulation of Polymers-Based Methotrexate Patches and Investigation of the Effect of Various Penetration Enhancers: In Vitro, Ex Vivo and In Vivo Characterization

Formulation of Polymers-Based Methotrexate Patches and Investigation of the Effect of Various Penetration Enhancers: In Vitro, Ex Vivo and In Vivo Characterization

Formulation and evaluation of Ketorolac tromethamine for transdermal drug delivery system

Test title

Contact Info

Product

Resources

About